Background and aims: Oxidative stress in patients with polycystic ovary syndrome causes a lot of problems and oxidized lipids increase the risk of many diseases. The aim of this study was to evaluate changes in malondialdehyde (MDA) following treatment with atorvastatin and omega-3. To identify the factors causing the decline lipid oxidation are particularly important in the management and treatment of these patients.

Methods: In this clinical trial study, patients with this syndrome were divided into three groups based on the visit. The first group, 26 patients consumed 4g per day omega -3. The second group, 27 patients consumed 20 mg per day atorvastatin and control group, 29 patients received placebo. After gathering all the samples using standard method for measuring lipid profile, the level of malondialdehyde was detected by the HPLC, insulin and testosterone were measured by ELISA. Data were analyzed with using paired t-test and ANOVA in SPSS software.

Results: Omega-3 supplementation decreased malondialdehyde and testosterone. It also had a positive effect on raising HDL-C. Atorvastatin only decreased malondialdehyde in the atorvastatin recipients.

Conclusion: Omega-3 supplements or atorvastatin in patients with polycystic ovary syndrome reduces the lipid oxidation and MDA level. It is expected to decrease the risk of cardiovascular diseases in patients with polycystic ovary syndrome by reduction of lipid oxidation.